Guangzhou Qinan Pharmaceutical Technology

Guangzhou Qinan Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in the Guangzhou International Bio Island, China. Founded in 2020, the company is dedicated to the discovery and development of innovative small molecule drugs targeting oncology and autoimmune diseases. Its lead clinical candidate, QN-001, is a novel small molecule inhibitor currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. Qinan Pharmaceutical employs a proprietary drug discovery platform to identify and optimize high-potential therapeutic candidates. The company aims to bridge the gap between basic research and clinical application to provide effective new treatments for patients with significant unmet medical needs.